Physician profile
Brian K Stein
NPI 1275649212
$7,787.28
in general payments reported to CMS, 2019-2025
38 companies · $1,735 in 2025
The $1,735 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $650 · 2020: $162 · 2021: $570 · 2022: $1,435 · 2023: $1,517 · 2024: $1,720 · 2025: $1,735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,971.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,487.44 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $1,393.13 | 2021-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals Lp | $769.85 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $446.53 | 2019-2025 | |
| Axsome Therapeutics, INC. | $429.81 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $337.51 | 2022-2025 | Caplyta |
| Exact Sciences Corporation | $312.14 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $255.52 | 2019-2024 | Veozah, Myrbetriq |
| Mylan Specialty L.P. | $223.02 | 2020-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $210.71 | 2019-2025 | Trintellix |
| Amarin Pharma, INC. | $198.08 | 2019-2022 | |
| Amgen INC. | $184.60 | 2021-2025 | Repatha, Evenity |
| Novo Nordisk INC | $160.62 | 2019-2025 | Wegovy |
| Abbott Laboratories | $150.42 | 2022-2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $148.37 | 2019-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.